Amgen Inc. reported that its fourth-quarter profit fell 8.5% because of decreased sales of the anemia drugs Epogen and Aranesp. The biotech company said its net income was $934 million, or $1.08 per share, down from $1.02 billion, or $1.08 per share, a year earlier. Revenue rose 3% to $3.97 billion.

Sales of Aranesp fell 15% to $538 million. Epogen sales dropped 18% to $486 million.

Sales for the drugs Neulasta and Neupogen, used to prevent infections in patients on chemotherapy, increased 7% to $1.32 billion.

Amgen also announced that it would pay $1.16 billion to buy drug developer Micromet Inc, which is testing a new treatment for leukemia and non-Hodgkin's lymphoma.